

7^ο ΚΡΗΤΟ-ΚΥΠΡΙΑΚΟ ΣΥΜΠΟΣΙΟ ΡΕΥΜΑΤΟΛΟΓΙΑΣ
Η ΡΕΥΜΑΤΟΛΟΓΑ ΣΗΜΕΡΑ-
ΠΡΑΚΤΙΚΑ ΠΡΟΒΛΗΜΑΤΑ ΤΗΣ ΚΑΘΗΜΕΡΙΝΗΣ ΚΛΙΝΙΚΗΣ ΠΡΑΞΗΣ
Κύπρος 23 Οκτωβρίου-25 Οκτωβρίου 2015

- i. Gene expression and regulation in SLE
- ii. Autophagy and SLE

Ελένη Α. Φράγκου, Νεφρολόγος
25/10/2015


7^ο ΚΡΗΤΟ-ΚΥΠΡΙΑΚΟ ΣΥΜΠΟΣΙΟ ΡΕΥΜΑΤΟΛΟΓΙΑΣ
Η ΡΕΥΜΑΤΟΛΟΓΑ ΣΗΜΕΡΑ-
ΠΡΑΚΤΙΚΑ ΠΡΟΒΛΗΜΑΤΑ ΤΗΣ ΚΑΘΗΜΕΡΙΝΗΣ ΚΛΙΝΙΚΗΣ ΠΡΑΞΗΣ
Κύπρος 23 Οκτωβρίου-25 Οκτωβρίου 2015

- i. Gene expression and regulation in SLE
- ii. Autophagy and SLE


Ελένη Α. Φράγκου, Νεφρολόγος
25/10/2015

SLE PATHOGENESIS IS COMPLEX

Lupus often starts at a young age. Very long disease course...



GENETIC CONTRIBUTION TO SLE IS ~30%



GENOME-WIDE ASSOCIATION STUDIES (GWAS)


>50 SLE-associated genes/loci

However,

- They explain only 10-20% of heritability
- Each variant has a small contribution to genetic risk
- Causal variants have not been identified


GENETIC CONTRIBUTION TO SLE IS ~30%

Genetic information is transferred from DNA to proteins through mRNA



GWAS – ENCODE Project

- 76% of human genome is transcribed
- **>90% of variants** associated with complex diseases **are located in non-coding regions**
- **SLE-associated variants:**
strongly enriched in enhancers
highly active in SLE-associated cell-types




✓ **Non-coding and regulatory genomes are important in human disease**

NOVEL APPROACHES TO CHARACTERIZE
NON-CODING AND REGULATORY GENOMES IN HUMAN DISEASE

NOVEL APPROACHES TO CHARACTERIZE NON-CODING AND REGULATORY GENOMES IN HUMAN DISEASE

A. HYBRIDIZATION-BASED TECHNOLOGIES (MICROARRAYS)




ADVANTAGES

- High throughput
- Inexpensive

LIMITATIONS

- High background
- Hybridization issues
- Difficult to quantify low-abundance transcripts
- *A priori* knowledge of sequences
- Difficult to identify *de novo* spliced isoforms
- Difficult to identify RNA editing
- Difficult to identify fusion transcripts


MOLECULAR SIGNATURE OF SLE



✓ **Unanswered questions and unmet needs still exist**

NOVEL APPROACHES TO CHARACTERIZE NON-CODING AND REGULATORY GENOMES IN HUMAN DISEASE


B. NEXT-GENERATION SEQUENCING TECHNOLOGIES: RNA-Seq



ADVANTAGES

Massively parallel sequencing
Discovery of low frequency variants
Association of variants with phenotypes

Identify *de novo*:
alternatively spliced or fusions transcripts
RNA-editing
allelic imbalance events



AIM OF THE STUDY

is to further investigate SLE etiopathogenesis
through a **comparative transcriptomic and genomic analysis** in

- A. murine lupus model
- B. in human LN

using RNA-Seq
(unbiased and not-requiring-*a priori* hypothesis NGS approach)

MATERIALS AND METHODS

1. MURINE STUDIES


Female NZB, NZW, NZB/W F1, B6

B6: not autoimmune


NZB, NZW: limited autoimmunity

NZB/W F1: lupus-like phenotype

classical model of human lupus



ANA
anti-dsDNA
Lymphadenopathy
Splenomegaly
Immune-complex GN




W

F1

MATERIALS AND METHODS

1. MURINE STUDIES



NEPHRITIC STAGE

Proteinuria >300 mg/d
for 3 consecutive days

MATERIALS AND METHODS

- **PERIPHERAL BLOOD COLLECTION** (serum autoantibody detection)
- **ANIMAL PERFUSION WITH PBS**
- **KIDNEYS, SPLEEN, BRAIN EXTRACTION, BM** (total RNA, protein, DNA)
- **KIDNEYS STORED** in paraffin blocks (RT), OCT (-80°C)
- **TOTAL RNA EXTRACTION** (Trizol-based method for RNA-seq)
- **DNA EXTRACTION** (GWAS to generate SNP datasets)

MATERIALS AND METHODS

2. **HUMAN STUDIES (MALES AND FEMALES)**

Frozen kidneys from proliferative LN (n=30)

Frozen normal kidneys adjacent to cancer (n=30)

*(Nephrology Department and Renal Histology Department
«Laiko» Hospital of Athens, University of Athens)*

- **TOTAL RNA EXTRACTION** (Trizol-based method for RNA-seq)
- **DNA EXTRACTION** (GWAS to generate SNP datasets)

MATERIALS AND METHODS

3. RNA-SEQUENCING

Illumina HiSeq Analyzer (*University of Geneva, Prof. E. Dermitzakis*)

- Each RNA sample (**1-2 µg of total RNA, A260/A280 > 1.8**) will be sequenced with **37-bp paired end in one sequencing lane**
- Each paired-end read will be **quantified for individual exons and genes** given known transcripts (mouse and human alignment)
- Each paired-end read will be **normalized for insert size variability** using regression
- Transcript abundance will also be **quantified using the FluxCapacitor** method

4. GWAS (Whole genome)

High-density exome core chips

SNP dataset generation for NZB/W-F1 and humans

RNA-SEQUENCING

Illumina GATK Analyzer

- ✓ quantify all coding, non coding and small RNAs
- ✓ map transcription start sites of genes
- ✓ map 5', 3'-ends of genes
- ✓ characterize alternative splicing patterns
- ✓ identify isoforms
- ✓ detect fusion transcripts
- ✓ determine post-transcriptional modifications
- ✓ identify endogenous viral sequences

Genome-Wide-Association Studies (GWAS)

- ✓ SNP DATA GENERATION

BIOINFORMATICS

NETWORKS

- ✓ Gene-Gene
- ✓ Gene-Environment
- ✓ Gene-Phenotype

eQTL MAPPING

- Genotype-to-gene expression level correlation determining
- ✓ phenotypic variation
 - ✓ susceptibility to LN

HUMAN-TO-ANIMAL COMPARATIVE ANALYSIS

- ✓ conserved transcriptional patterns
- ✓ differentially expressed patterns
- ✓ common differentially expressed patterns

NETWORK HUMBS, eQTLs, AND COMMON DIFFERENTIALLY EXPRESSED GENES REPRESENT TOOLS TO STUDY

- ✓ novel molecular mechanisms in LN
- ✓ novel therapeutic targets in LN
- ✓ differential response to treatment in LN

DIFFERENTIALLY EXPRESSED GENE TRANSCRIPTS

1. represent tools to study **novel molecular mechanisms** and **novel therapeutic targets**
2. could be used as **biomarkers** of disease activity, severity, morbidity and response to therapy

7^ο ΚΡΗΤΟ-ΚΥΠΡΙΑΚΟ ΣΥΜΠΟΣΙΟ ΡΕΥΜΑΤΟΛΟΓΙΑΣ
Η ΡΕΥΜΑΤΟΛΟΓΑ ΣΗΜΕΡΑ-
ΠΡΑΚΤΙΚΑ ΠΡΟΒΛΗΜΑΤΑ ΤΗΣ ΚΑΘΗΜΕΡΙΝΗΣ ΚΛΙΝΙΚΗΣ ΠΡΑΞΗΣ
Κύπρος 23 Οκτωβρίου-25 Οκτωβρίου 2015

- i. Gene expression and regulation in SLE
- ii. Autophagy and SLE


Ελένη Α. Φράγκου, Νεφρολόγος

25/10/2015

INTRODUCTION

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Active SLE patients express a strong neutrophil signature



SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)


Active SLE patients are characterized by
upregulation of **autophagy genes**
and by differential expression of **miRs targeting autophagy genes**

miR microarray analysis (PBMC)

microRNA	Predicted gene targets	microRNA	Predicted gene targets
hsa-miR-296	HIPK1, EPN1, SRF	hsa-miR-21	PDCD4, TPM1, PLAG1
hsa-miR-196a	HOXC8, HOXA7, SOCS4	hsa-miR-342	RASSF1, JMJD3, SOX6
hsa-miR-17-5p	PPARA, E2F1, PKD2	hsa-miR-214	TRAF7, MNT, NARG1
hsa-miR-383	MAL2, MGA, IRF1	hsa-miR-494	SOC S6, NOVA1, PTEN
hsa-miR-184	SF1, PPP1CC, ELN	hsa-miR-198	BMF, PBX1, BAX
hsa-miR-379	GDF6, INSR, SEMA3A	hsa-miR-155	PU,1, FADD, C-MAF
hsa-miR-15a	BCL2, CDK6, FGF2	hsa-miR-25	BIM, NFAT5, CD69
hsa-miR-16	BCL2, FGF2, CCND2	hsa-miR-106b	CDKN1A, BTG1, NFAT5
hsa-miR-150	ELK1, C-MYB, IRAK2	hsa-miR-373	MTF1, PARP8, PCAF
hsa-let-7a	STAT3, C-MYC, HMGA2	hsa-miR-324-3p	DAG1, TRAF7, CHES1
hsa-let-7d	HMGA2, IGF2BP1, TRIM7	hsa-miR-544	FOXO1A, ABI2, TOX
hsa-let-7g	HMGA2, YOD1, TBFBR1	hsa-miR-148a	KIS, DNMT3B, MEOX2
hsa-miR-98	EPHA4, FIGN, IGF1R	hsa-miR-148b	MITF, DNMT3B, MEOX2
hsa-miR-532	CPEB3, PAK4, IRS2		

AUTOPHAGY


- **Homeostatic catabolic mechanism**
- Cells break their own components
- Is involved in cellular processes:
cell cycle, energy regulation, **immune response**



WHAT IS THE MECHANISM OF TISSUE INJURY IN SLE?

PMNs and NETosis

- **Novel form of cell death**
- PMNs release chromatin filaments decorated with proteins and enzymes released from granules (MPO, elastase, cathepsins etc)
- **Neutrophil Extracellular Traps (NETs)**
- Implicated in several diseases: **SLE**




TISSUE FACTOR (TF)

is the main *in vivo* coagulation initiator

Through TF-thrombin axis: **coagulation cascade**

Through PAR activation: **inflammation**



In PMNs:

Intracellular localization of TF

Extracellular delivery of TF through NETs

HYPOTHESIS

In SLE patients, autophagy mediates the delivery of TF to NETs

AIM OF THE STUDY

is to investigate the role of TF-decorated NETs in SLE

MATERIALS AND METHODS

Subjects enrolled *	Healthy Individuals	Active SLE patients	SLE patients on hydroxychloroquine
NUMBER	16	14	4
SEX			
Males	10 (63%)	1 (7%)	0 (0%)
Females	6 (37%)	13 (93%)	4 (100%)
MEAN AGE (years)	30.4	28.35	?
SELENA SLEDAI SCORE	-	>6	
Anti-PL abs	-	3	0


* Subjects receiving anti-PLTs or anticoagulants were excluded

MATERIALS AND METHODS

Serum and PMNs isolation (double gradient centrifugation - Ficolls)

PMNs viability >95% (Trypan blue staining)


PMNs purity >95% (**Giemsa staining**)




RESULTS

1. ACTIVE LUPUS PMNs EXPRESS INCREASED AUTOPHAGY LEVELS

A. Immunofluorescence for LC3B






B. Immunoblotting for LC3




2. ACTIVE LUPUS PMNs UNDERGO INCREASED NETOSIS IN AN AUTOPHAGY-DEPENDENT MANNER

A. Immunofluorescence for MPO/DAPI




B. MPO/DNA complex ELISA in serum




3. AUTOPHAGY MEDIATES THE RELEASE OF ACTIVE TF ON SLE NETs, LEADING TO TROMBIN GENERATION

A. Immunofluorescence for TF/LC3/DAPI





B. Thrombin-antithrombin complex assay




4. SLE SERUM INCREASES AUTOPHAGY IN HEALTHY PMNs


A. Immunofluorescence for LC3



B. Immunoblotting for LC3 and p62




C. RT-PCR for ATG3 expression




5. SLE SERUM INDUCES AUTOPHAGY-DEPENDENT NET RELEASE

A. Immunofluorescence for MPO/DAPI




B. MPO/DNA complex ELISA in NET structures




6. SLE SERUM UPREGULATES TF LEVELS IN HEALTHY PMNS AND INDUCES TF-DECORATED NETOSIS IN AN AUTOPHAGY-DEPENDENT MANNER


A. Immunofluorescence for TF/DAPI



B. Immunoblotting for TF



7. TF-DECORATED NETs INFILTRATE THE KIDNEYS OF PATIENTS WITH LN




CONCLUSIONS

- ✓ PMNs from active SLE patients express **increased autophagy levels**
- ✓ PMNs from active SLE patients release **TF-decorated NETs in an autophagy-dependent** manner, leading to **thrombin generation**
- ✓ TF-decorated NETs **infiltrate the kidneys of LN patients**
- ✓ Ongoing experiments investigate the role of TF-decorated NETs on renal injury

DISCUSSION

- NETs are scaffolds with accumulated bioactive molecules
- NETs remain in target tissues even when PMNs are not present



- ✓ Inflammation and hypercoagulation in SLE
- ✓ Glomerular microthrombi deposition and glomerular endothelial injury

Kambas K Ann Rheum Dis. 2013

EULAR/ERA-EDTA recommendations for the management of LN. Bertias GK. Ann Rheum Dis. 2012

ΕΥΧΑΡΙΣΤΩ

Prof D.T. Boumpas

Dr G. Bertsiias

Dr P. Verginis

Dr M. Zavros

